A pharmaceutical company engaged in the R&D, production and sales of chemical preparations, APIs and intermediates, while strategically expanding into new energy materials such as lithium battery electrolyte additives and solid-state battery materials.
INVESTMENT RATINGD-GRADE
MARKET CAP (USD)加载中...
EXCHANGESZSE
INDUSTRY / SUB-INDUSTRY
Pharmaceuticals/Chemical Pharmaceuticals
财务信息
2025 FY经营现金流: $10.8M
营业收入 (Revenue)$92.81M
净利润 (Net Income)$5.82M
毛利率 (Gross Margin)82.5%
净利润率 (Net Margin)6.3%
个人看法
ROE is too low, and it has essentially no moat. The company is small in overall scale, with a fragmented product mix.
PRO RESEARCH REPORT~3000 words
Hicin Pharmaceutical (300584.SZ): Dual-Engine Strategy — Pharmaceutical Base with New Energy Second Curve
EXECUTIVE SUMMARY / 研报摘要
Nanjing Hicin Pharmaceutical, listed on the ChiNext Board of the Shenzhen Stock Exchange (ticker: 300584.SZ), is a pharmaceutical enterprise centered on the R&D, production and sales of chemical preparations, APIs and intermediates, while strategically extending into new energy materials via a technology-sharing platform. In FY2025, the company generated revenue of approximately $92.81 million, representing a YoY growth of 33.05%, and net income attributable to shareholders of approximately $5.82 million. Gross margin stood at a high level of 82.51%, reflecting the profitability of its core pharmaceutical products, particularly Landiolol Hydrochloride for Injection, which holds a domestic exclusive first-generic status. The company is actively cultivating a second growth curve in lithium battery electrolyte additives and solid-state battery materials, with the VC additive business beginning to contribute revenue. However, it faces challenges including declining net margin due to non-recurring investment losses, narrowing revenue from centralized procurement drugs, and an early-stage new energy business that has not yet formed large-scale orders. The investment thesis hinges on the commercialization progress of its lithium materials pipeline and the sustainability of its core pharmaceutical product growth.
1. Company Overview
Nanjing Hicin Pharmaceutical CO.,LTD. (stock ticker: 300584.SZ) is a pharmaceutical company listed on the ChiNext Board of the Shenzhen Stock Exchange since January 12, 2017. Headquartered in Nanjing, Jiangsu Province, the company was founded in January 2003 and has developed a comprehensive portfolio of chemical preparations, active pharmaceutical ingredients (APIs), and intermediates. The company operates primarily in the pharmaceutical manufacturing sector, with its business scope covering drug production, pharmaceutical product development, plant extract production, and import-export trade of pharmaceuticals and raw materials.
As of the end of FY2025, Hicin Pharmaceutical employed 553 people, with per-capita revenue generation of approximately RMB 1.21 million and per-capita profit of RMB 76,100. The company holds 81 drug approval numbers or registration certificates for preparations and APIs, with its major products included in the 2025 National Medical Insurance Catalog. While the pharmaceutical business remains the core foundation, the company has been actively expanding into new energy materials, positioning itself within the lithium battery supply chain, particularly in electrolyte additives and solid-state battery materials.
2. Business Model & Core Operations
The company's business model is built on a dual-engine strategy: a stable pharmaceutical base complemented by an emerging new energy materials segment. In the pharmaceutical segment, Hicin Pharmaceutical engages in the R&D, production, and sales of chemical preparations, APIs, and intermediates, with products covering therapeutic areas including cardiovascular and cerebrovascular diseases, diuretics, anti-infectives, digestive system, immunomodulation, hypoglycemics, and orthopedics. The company maintains over 20 products in active production and utilizes a professional evidence-based medical promotion model, primarily through a distributor agency system with hospital terminal and third-terminal teams.
The new energy materials business is operated through its holding subsidiary, Anqing Huichen Technology Co., Ltd., which independently conducts lithium material operations. The company has established a stable supply relationship with mainstream domestic electrolyte customers and is in the capacity ramp-up phase, with monthly capacity reaching 300-400 tons. The company is focusing on four core product matrices: lithium battery electrolyte additives, lithium sulfide, sulfide solid-state electrolytes and membranes, and solid-state battery binders. This strategic diversification leverages the company's expertise in chemical synthesis and technology-sharing platforms to capture opportunities in the rapidly growing new energy sector.
3. Market Position & Competition
In the pharmaceutical sector, Hicin Pharmaceutical occupies a niche position with a focus on differentiated, high-value generic drugs. Its flagship product, Landiolol Hydrochloride for Injection (brand name: Zexing), is a domestic exclusive first-generic drug with few competitors. As a highly selective short-acting beta-1 receptor blocker, Landiolol has been recommended in multiple authoritative guidelines including the European 2024 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation and the Chinese Atrial Fibrillation Management Guidelines (2025). The product was successfully renewed through the national medical insurance negotiation in 2021 and again in 2023, with the 50mg specification renewed and the 150mg specification newly included in the 2025 National Medical Insurance Catalog.
Other key products include Rivaroxaban Tablets, which won the bid in the fifth national centralized procurement in 2021 and was subsequently re-selected in the Jiangsu Province alliance procurement in 2024, supplying multiple provinces. Tigecycline for Injection addresses complex infections and overcomes major antibiotic resistance mechanisms. The company's competitive advantage lies in its focus on first-generic drugs and high-barrier formulations, which offer higher margins and less intense competition compared to standard generics. However, the company faces pressure from centralized procurement policies that have eroded revenue from certain non-differentiated products.
4. AI & Semiconductor Alignment
Hicin Pharmaceutical has explicitly stated that it has no plans to enter the chip or semiconductor field. In response to investor inquiries, the company confirmed that there is no business layout plan in the chip sector. The company's strategic focus is directed toward the pharmaceutical and new energy materials sectors, not semiconductors or AI-related applications. This makes Hicin Pharmaceutical distinctly different from companies that are actively pursuing semiconductor or AI opportunities. However, the company does possess some exposure to electronic materials through its subsidiary Sichuan Luochen New Material Technology Co., Ltd., which was jointly established by Anqing Huichen and Saike Power, with a business scope including electronic special material manufacturing and sales. This subsidiary is primarily focused on new energy and electronic materials, including solid-state battery binders, rather than semiconductor applications.
5. Customer & Regional Analysis
The company's sales network covers most provinces, autonomous regions, and municipalities in China. As of recent years, Hicin Pharmaceutical maintained 28 offices nationwide, with over 50 marketing management personnel and nearly a thousand terminal promotion staff, cooperating with nearly 200 key pharmaceutical commercial units. In terms of regional revenue distribution, East China represents the largest market, accounting for approximately 39.86% of revenue, followed by North China and other regions.
In the pharmaceutical segment, the company serves hospitals across the country, with its products covered in Grade A tertiary hospitals nationwide, particularly through the promotion of its core product Landiolol. In the new energy materials segment, the company has established stable supply relationships with mainstream domestic electrolyte customers and is in the capacity ramp-up phase, with potential for further volume growth as production capacity increases. The customer concentration in the new energy segment is expected to be relatively high in the initial stage, given the limited number of major electrolyte producers in China.
6. Economic Moat Analysis
Hicin Pharmaceutical's economic moat is primarily derived from its high-barrier first-generic drugs, particularly Landiolol Hydrochloride for Injection, which enjoys a domestic exclusive status with few competitors. This exclusivity, combined with its inclusion in the National Medical Insurance Catalog, provides a stable revenue stream and pricing advantage. The company has also built an integrated R&D system covering API/intermediate development, quality research, and formulation development, supported by over 60 R&D personnel and advanced domestic scientific research equipment. The company has been recognized in the 'China Chemical Pharmaceutical Enterprise TOP100' list for consecutive years, demonstrating its industry standing.
Furthermore, the company's strategic layout in the new energy materials sector, particularly in solid-state battery materials such as lithium sulfide with purity exceeding 99.9%, positions it favorably for the emerging solid-state battery industry. The company's liquid-phase method for lithium sulfide production offers cost and purity advantages compared to traditional solid-phase methods, creating a potential technological barrier in this nascent field. However, the new energy business is still in its early stages, and the moat in this segment is not yet fully established.
7. Unique Competitive Advantages
The company's unique competitive advantages stem from its dual focus on high-value pharmaceuticals and forward-looking new energy materials. In the pharmaceutical sector, the company's strategy of focusing on first-generic and high-barrier formulations, rather than competing in the crowded generic market, allows it to maintain superior margins. The company's R&D direction has accelerated the transition from ordinary generics to clinically valuable first-generic drugs and innovative drugs, building a 'imitation-innovation' dual-track development pattern.
In the new energy sector, the company's early positioning in solid-state battery materials, including lithium sulfide, solid-state electrolytes, and specialized binders, provides a first-mover advantage in a market with significant long-term growth potential. The company's sulfate ester additives, a new type of sulfur-based additive that improves high-temperature storage and cycling stability of batteries, are produced by only a limited number of domestic enterprises, giving Hicin a differentiated competitive position in this niche. Additionally, the company's controlling shareholder has fully released share pledges, indicating confidence and stability in the company's ownership structure.
8. R&D and Technological Capability
The company maintains a strong commitment to research and development. Its R&D center, established at the company's inception, employs over 60 researchers and is equipped with advanced domestic scientific research instruments. The company has built a complete R&D system covering API/intermediate development, quality research, and formulation development. In 2025, the company continued to improve its R&D system, optimizing project management and quality management processes, and accelerating the standardization of technology transfer management.
In the new energy materials domain, the company has made significant technological progress. Its lithium sulfide pilot line has been completed and entered the customer sampling preparation stage, with product purity reaching over 99.9%, meeting the requirements of downstream customers. The company is advancing sampling verification and plans to initiate a hundred-ton production line after successful validation. For solid-state battery binders, the company is collaborating with Saike Power on pilot-scale process development, with Anqing Huichen responsible for pilot-scale amplification and commercial mass production, expected to complete pilot-scale process handover in 2026.
9. Industry Analysis
The pharmaceutical industry in China is undergoing significant transformation driven by healthcare reform, centralized procurement policies, and an aging population. The centralized procurement policy has fundamentally altered the competitive landscape for generic drugs, eroding margins for products lacking differentiation. However, this environment also creates opportunities for companies like Hicin Pharmaceutical that focus on high-barrier first-generic drugs and innovative formulations. The cardiovascular and cerebrovascular segment, which accounts for 83.98% of the company's pharmaceutical revenue and achieved a gross margin of 93.03%, remains a key growth driver.
The new energy materials industry, particularly the lithium battery supply chain, continues to experience robust growth driven by the global transition to electric vehicles and renewable energy storage. The electrolyte additive market, including VC and sulfate ester additives, is benefiting from the rapid expansion of lithium battery production. More importantly, the emerging solid-state battery technology represents a paradigm shift with the potential to revolutionize energy storage, and materials like lithium sulfide and solid-state electrolytes are critical to this transition. While the solid-state battery industry is still in its early commercialization phase, companies that establish technological leadership and supply chain positioning early may capture significant value as the technology matures.
10. Investment Conclusion & Enterprise Quality
Hicin Pharmaceutical presents a dual-growth thesis: a stable and profitable pharmaceutical business anchored by a domestic exclusive first-generic drug, and an emerging new energy materials business that offers optionality in the fast-growing solid-state battery supply chain. The company's FY2025 financial performance demonstrates the strength of its core pharmaceutical business, with revenue growth of 33.05% and a gross margin of 82.51%. The net income growth of only 4.58% was primarily due to non-recurring investment valuation losses, while adjusted net profit (excluding non-recurring items) grew 48.40%, reflecting the underlying operational strength.
The company's key investment catalysts include: first, the continued volume growth of Landiolol following its inclusion in the National Medical Insurance Catalog with the new 150mg specification; second, the ramp-up of VC electrolyte additives and other lithium materials that are already contributing revenue; and third, the potential commercialization of its solid-state battery material pipeline, including lithium sulfide and specialized binders. However, investors should note the risks: the new energy materials business is still in its early stages with no significant orders yet, the pharmaceutical business faces ongoing pressure from centralized procurement on non-core products, and the company's return on invested capital has been historically modest at 3.46% in 2025. The company's current valuation reflects high growth expectations, with a P/E ratio significantly above the industry average, suggesting that successful execution of its new energy strategy is critical to justifying the premium valuation. Overall, Hicin Pharmaceutical represents a story of transformation from a niche pharmaceutical player to a dual-track enterprise, with the pharmaceutical business providing stability and the new energy materials business offering long-term growth potential.